Mevalonate pathway is a novel target for hypertension

Circulation Journal

Volumn 75, Issue 6, 2011, Pages 1318-1319

  Kishi, Takuya ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESYL TRANSFERASE ALPHA; FARNESYL TRANSFERASE BETA; FASUDIL; GERANYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVALONIC ACID; RAC PROTEIN; RAP PROTEIN; RAS PROTEIN; RHO FACTOR; SQUALENE SYNTHASE; TRANSFERASE; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; DRUG MECHANISM; EDITORIAL; ENZYME INHIBITION; HUMAN; HYPERTENSION; ISOPRENYLATION; NONHUMAN; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BLOOD PRESSURE; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; FARNESYLTRANSTRANSFERASE; GERANYLTRANSTRANSFERASE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERTENSION; MEVALONIC ACID; MYOCARDIUM; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 79957737989     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0401     Document Type: Editorial

References (15)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
2. Van Aelst L, D'Souza-Schorey C. RhoGTPase and signaling networks. Genes Dev 1997; 11: 2295-2322.
3. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: A decade of hypertrophic signaling hits. Circ Res 2006; 98: 730-742.
4. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
5. Laufs U, Kilter H, Konkol C, Wassmann S, Bohm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002; 53: 911-920.
6. Rikitake Y, Hirata K. Inhibition of rhoa or Rac1? Mechanisms of cholesterol-independent beneficial effects of statins. Circ J 2009; 73: 231-232.
7. Zhou Q, Liao JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J 2010; 74: 818-826.
8. Han J, Jiang DM, Du CQ, Hu SJ. Alteration of enzyme expressions in mevalonate pathway: Possible role for cardiovascular remodeling in spontaneously hypertensive rats. Circ J 2011; 75: 1409-1417.
9. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007; 28: 296-302.
10. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 2009; 73: 361-370.
11. Kishi T, Hirooka Y, Masumoto A, Inokuchi K, Ito K, Sakai K, et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of forearm in patients with heart failure. Circulation 2005; 111: 2741-2747.
12. Hirooka Y, Shimokawa H. Therapeutic potential of Rho-kinase inhibitors in cardiovascular diseases. Am J Cardiovasc Drugs 2005; 5: 31-39.
13. Kishi T, Hirooka Y, Konno S, Koga Y, Araki S, Sunagawa K. Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2010; 55: 184-190.
14. Kishi T, Hirooka Y, Konno S, Ogawa K, Sunagawa K. Angiotensin II type 1 receptor-activated caspase-3 through ras/mitogen-activated protein kinase-extracellular signal-regulated kinase in the rostral ventrolateral medulla is involved in sympathoexcitation in strokeprone spontaneously hypertensive rats. Hypertension 2010; 55: 291-297.
15. Kishi T, Hirooka Y. Sympatho-inhibitory effects of atorvastatin in hypertension. Circ J 2010; 74: 2552-2553.